Global Personalized Gene Therapy Treatment Market Report 2025: Outlook on Opportunities & Challenges

 Claim 30% Off With Code ONLINE30 — Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights

 

 What Is the Forecasted Market Size of the Personalized Gene Therapy Treatment Market by 2029?
 The personalized gene therapy treatment market size has grown exponentially in recent years. It will grow from $6.93 billion in 2024 to $8.38 billion in 2025 at a compound annual growth rate (CAGR) of 20.8%. The growth in the historic period can be attributed to increasing prevalence of genetic disorders, advancements in gene editing technologies, rising awareness about personalized medicine, supportive government initiatives and funding, and growth in biotechnology research and infrastructure.
 
 The personalized gene therapy treatment market size is expected to see exponential growth in the next few years. It will grow to $17.65 billion in 2029 at a compound annual growth rate (CAGR) of 20.5%. The growth in the forecast period can be attributed to the expansion of clinical trials for gene therapies, the integration of AI and predictive analytics in treatment design, increasing partnerships between pharma and biotech companies, the development of safer and more efficient delivery vectors, and the growing demand for targeted and precision therapies. Major trends in the forecast period include integration of artificial intelligence and machine learning in therapy design, expansion of genomic sequencing capabilities, rising collaborations between biotechnology and pharmaceutical companies, automation in gene therapy manufacturing processes, and integration of blockchain technology for genetic data security.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=28293&type=smp
  
 Which Drivers Are Positively Impacting the Personalized Gene Therapy Treatment Market?
 The growing prevalence of genetic disorders is expected to propel the growth of the personalized gene therapy treatment market going forward. Genetic disorders are conditions resulting from DNA abnormalities that disrupt normal body functions. The prevalence of genetic disorders is rising due to increasing parental age, as older reproductive cells have a higher risk of mutations that can be passed to offspring. Personalized gene therapy addresses genetic disorders by precisely correcting the defective genes responsible for the condition and tailors treatment to an individual’s genetic makeup, enhancing efficacy and reducing side effects. For instance, in September 2023, according to the Cystic Fibrosis Trust, a UK-based national charity, in the UK, 11,148 patients were registered with cystic fibrosis (CF) in 2022, an increase from 10,908 in 2021. Therefore, the growing prevalence of genetic disorders is driving the growth of the personalized gene therapy treatment market.
 
 Which Are the Leading Segments in the Personalized Gene Therapy Treatment Market by Revenue?
 The personalized gene therapy treatment market covered in this report is segmented as
 
 1) By Therapy: Targeted Treatments, Pharmacogenomics
 2) By Vector Type: Viral, Non-Viral
 3) By Distribution Channel: Hospitals, Clinics, Home Administration, Other Distribution Channels
 4) By Application: Oncology, Neurology, Hematological, Infectious Diseases, Ophthalmology, Other Applications
 
 Subsegments:
 1) By Targeted Treatments: Monoclonal Antibodies, Chimeric Antigen Receptor T-Cell Therapy (CAR-T), Small Interfering RNA (siRNA) Therapy, Antisense Oligonucleotides (ASO), Gene Editing Therapy
 2) By Pharmacogenomics: Companion Diagnostics, Drug Metabolism Enzyme Testing, Genetic Biomarker Analysis, Single Nucleotide Polymorphism (SNP) Profiling, Adverse Drug Reaction (ADR) Prediction
 
 What Are the Major Trends Impacting the Personalized Gene Therapy Treatment Market?
 Major companies operating in the personalized gene therapy treatment market are focusing on adopting strategic partnerships to expand technological capabilities and bring innovative therapies to patients more efficiently. Strategic partnerships are collaborative alliances between organizations to leverage each other’s strengths and resources for mutual growth and competitive advantage while sharing risks and benefits. For instance, in May 2025, Aldevron, a US-based company involved in the production of DNA, RNA, and protein, collaborated with Integrated DNA Technologies, a US-based provider of genomics solutions, to manufacture the world’s first mRNA-based personalized CRISPR therapy to treat an infant with a rare and life-threatening genetic condition, urea cycle disorder (UCD). This N of 1 therapy was developed and delivered in just six months by creating a custom guide RNA, an mRNA-encoded base editor, off-target safety services, and a clinically validated lipid nanoparticle delivery system. The therapy’s development marks a significant milestone in personalized in vivo base-editing treatments.
 
 Who Are the Top Companies Contributing to the Personalized Gene Therapy Treatment Market Expansion?
 Major companies operating in the personalized gene therapy treatment market are Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Kyowa Kirin Co. Ltd., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Rocket Pharmaceuticals Inc., REGENXBIO Inc., Intellia Therapeutics Inc., Beam Therapeutics Inc., Adaptimmune Therapeutics plc, Krystal Biotech Inc., Miltenyi Biomedicine GmbH, Bluebird Bio Inc., uniQure N.V., Mesoblast Limited, Astellas Gene Therapies Inc., Adverum Biotechnologies Inc., Autolus Therapeutics plc.
 
 Get the full personalized gene therapy treatment market report here:
 https://www.thebusinessresearchcompany.com/report/personalized-gene-therapy-treatment-global-market-report
 
 How Are Market Trends Differentiating Across Key Regions in the Personalized Gene Therapy Treatment Market?
 North America was the largest region in the personalized gene therapy treatment market in 2024. The regions covered in personalized gene therapy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company